Literature DB >> 21913968

HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes.

D Kerr1, H Partridge, J Knott, P W Thomas.   

Abstract

AIMS: To determine 5-year mortality rates, following the diagnosis of Type 2 diabetes, in a large local cohort of individuals with new onset of Type 2 diabetes seen within a few weeks of diagnosis in a single, community-based education programme.
METHODS: We reviewed referrals for people with Type 2 diabetes to our service over 5 years from 1999 to 2003 and determined, via regression analysis, which factors contributed significantly to mortality rates up to the end of 2007.
RESULTS: A total of 3781 new referrals were reviewed with an approximate doubling of referral rates over 5 years (546 in 1999-997 in 2003). Although the number of people developing the condition has increased, mortality rates over the 5 years from diagnosis has fallen from 11% in 1999-9% in 2003 (P < 0.005) Age at diagnosis was the strongest predictor of mortality (P < 0.001) but HbA(1c) at 3 months after diagnosis (P < 0.001), systolic (P < 0.001) and diastolic (P = 0.05) blood pressure, smoking status (P < 0.001) and gender (P = 0.04) were also significant predictors.
CONCLUSIONS: Our retrospective analysis adds weight to evidence suggesting that referral rates for people with Type 2 diabetes are increasing rapidly and that mortality rates are reducing but that the reasons for this are multifactorial. In addition to blood pressure, smoking and gender, the HbA(1c) achieved 3 months after the initial diagnosis also appears to predict subsequent mortality. It may be appropriate to consider early and intensive intervention for individuals with new onset type 2 diabetes.
© 2011 The Author. Diabetic Medicine © 2011 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21913968     DOI: 10.1111/j.1464-5491.2011.03443.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

Review 1.  The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies.

Authors:  Luke W Arnold; Zhiqiang Wang
Journal:  Rev Diabet Stud       Date:  2014-08-10

2.  Low HbA1c and mortality: causation and confounding.

Authors:  M K Rutter
Journal:  Diabetologia       Date:  2012-07-18       Impact factor: 10.122

Review 3.  Translating the advanced glycation end products (AGEs) knowledge into real-world nutrition strategies.

Authors:  Heitor O Santos; Nilson Penha-Silva
Journal:  Eur J Clin Nutr       Date:  2021-10-21       Impact factor: 4.884

4.  Incidence and associated risk factors for premature death in the Tehran Lipid and Glucose Study cohort, Iran.

Authors:  Ali Eslami; Seyed Sina Naghibi Irvani; Azra Ramezankhani; Nazanin Fekri; Keyvan Asadi; Fereidoun Azizi; Farzad Hadaegh
Journal:  BMC Public Health       Date:  2019-06-10       Impact factor: 3.295

5.  Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study.

Authors:  Martin B Whyte; Mark Joy; William Hinton; Andrew McGovern; Uy Hoang; Jeremy van Vlymen; Filipa Ferreira; Julie Mount; Neil Munro; Simon de Lusignan
Journal:  Diabetes Obes Metab       Date:  2022-04-18       Impact factor: 6.408

6.  Combining glycosylated hemoglobin A1c and fasting plasma glucose for diagnosis of type 2 diabetes in Chinese adults.

Authors:  Miao Mo; Weijian Zhong; Genming Zhao; Ye Ruan; Hua Zhang; Liang Shi; Dajiang Lu; Qundi Yang; Yanyun Li; Qingwu Jiang; Rui Li; Wang-Hong Xu
Journal:  BMC Endocr Disord       Date:  2013-10-08       Impact factor: 2.763

7.  Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study.

Authors:  Fumie Ikeda; Yasufumi Doi; Toshiharu Ninomiya; Yoichiro Hirakawa; Naoko Mukai; Jun Hata; Kentaro Shikata; Daigo Yoshida; Takayuki Matsumoto; Takanari Kitazono; Yutaka Kiyohara
Journal:  Cardiovasc Diabetol       Date:  2013-11-07       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.